Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
What each said, in their own words
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
The Avicenna Alliance supports the Commission’s ambition to revise the EU’s general pharmaceuticals legislation as it represents an ideal opportunity to update the regulatory framework to reflect the uptake of new technologies, including in silico technologies such as Computer Modelling and Simulation (CM&S), for medicinal products including combination products and Advanced therapy medicinal products (ATMPs). 1.
BEUC supports the European Commission’s initiative to evaluate and revise the general pharmaceutical legislation to improve access to medicines. We agree with the main gaps identified in the roadmap and corrective measures, but have additional recommendations. These are the most pressing issues and necessary changes for consumers: Unmet medical needs: Antimicrobial resistance is a global public health-threat.
The Avicenna Alliance represents a collaborative effort among stakeholders committed to advancing in silico medicine. This initiative harnesses the power of computer modelling and simulation to revolutionize the development and delivery of innovative medical treatments.
The Avicenna Alliance represents a collaborative effort among stakeholders committed to advancing in silico medicine. This initiative harnesses the power of computer modelling and simulation to revolutionize the development and delivery of innovative medical treatments.
The European Commission proposal for a revised EUs pharmaceutical legislation is a step in the right direction as it includes recommendations from BEUC on ways to improve access to medicines in Europe. We strongly support measures to increase transparency on public funding for biomedical research, facilitate the development of medicines by non-profit entities, and enhance EU cooperation and action in the prevention…
The European Health Data Space (EHDS) covering the exchange and access of primary and secondary use of good quality health data is eagerly awaited by the Avicenna Alliance to pursue scientific research and innovations, including the use of computer modelling and simulation (CM&S) in healthcare.
BEUC, The European Consumer Organisation appreciates the opportunity to provide input to the European Commission’s ongoing evaluation of the need for a legislative proposal on a European Health Data Space. We consider that the evaluation provides a timely opportunity to ensure that sensitive data of European patients and consumers used for scientific advancements is well protected and serves societal interests.
The Avicenna Alliance welcomes the proposal for the EHDS. The Alliance is a multistakeholder group with the mission of accelerating medical innovation and its practical implementation to ensure safe, affordable and cost-effective health care through the large-scale adoption of in silico medicine and computer modelling and simulation (CM&S).
Take this comparison with you
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.